Quick Read Hims scaled to $2.2B in revenue and 2.7M subscribers but margins fell from 6.5% to 2% as infrastructure spending surged. Subscriber growth slowed

Novo Nordisk just pulled off something nobody saw coming  Yahoo Finance Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street

Semaglutide use is linked to fewer hospitalizations and fewer days in the hospital for patients with cardiovascular disease and overweight or obesity, signaling benefits beyond

For all of the political chaos that American science endured in 2025, aspects of this country’s research enterprise made it through somewhat … okay. The

Elie Dolgin, IEEE Spectrum Christina had tried dieting and exercise before. The weight always came off but then crept back on, especially after she gave…

GLP-1 shots are a hot topic among the beauty and wellness community, often described as celebrities’ best-kept secret behind their miraculous weight loss. The… The

Novo Nordisk A/S (NYSE:NVO) is one of the best affordable healthcare stocks to buy now. On December 22, Novo Nordisk A/S (NYSE:NVO) announced the FDA approval

Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine from Eli Lilly, as

Amanda Bynes has offered a candid update on her ongoing weight loss journey. On December 22, the former Nickelodeon star reposted a viral paparazzi photo

Habener led research that discovered the GLP-1 hormone, a key ingredient in Ozempic and Mounjaro.

As 2025 comes to a close, we’re taking a look back at the Food Industry Executive articles that resonated most with our readers this year. 

Post Content

Lupin has signed an exclusive licensing, supply and distribution deal with China’s Gan & Lee for Bofanglutide, a fortnightly GLP-1 injectable for diabetes and weight

A new paper suggests that a widely used questionnaire for triaging mental health symptoms could be giving providers poor data to inform treatment—and that a

CMS Administrator Mehmet Oz, MD, has moved quickly to advance President Donald Trump’s “Make America Healthy Again” agenda in 2025. The push comes after President

Comfort.  We all seek it, and many try to find it in food. But comfort food often gives only a few minutes of satisfaction before

Artisan Partners, an investment management company, released its “Artisan Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The

Some people are hitting a weight loss plateau with GLP-1 agonist drugs like Ozempic, so they’re turning to a stronger variety that promises even more

Christina had tried dieting and exercise before. The weight always came off but then crept back on, especially after she gave birth to her son

Anecdotal stories suggesting that weight-loss drugs can help people shake long-standing addictions have been spreading fast in the past few years, through online forums, weight-loss

IJMS, Vol. 27, Pages 369: More than Dysbiosis: Imbalance in Humoral and Neuronal Bidirectional Crosstalk Between Gut and Brain in Alzheimer’s Disease International Journal of

Pills, TikTok and weight-loss apps: the consumer-driven future of GLP-1s​  Reuters Devices Target the Gut to Maintain Weight Loss from GLP-1 Drugs  IEEE Spectrum Considering Taking A

The recent U.S. Food and Drug Administration (FDA) approval of Novo Nordisk’s NVO oral obesity pill, Wegovy, marks a significant turning point in the fiercely

We recently published Big Winners: 10 Stocks Refusing to take a Holiday. Novo Nordisk A/S (NYSE:NVO) is one of the last week’s best performers. Novo

“When human beings have a love for money, and power, and push to control other human beings, there is an interest in us not getting

Novo Nordisk just pulled off something nobody saw coming  thestreet.com Weight-loss pill approval set to accelerate food industry product overhauls  Reuters FDA approves Novo Nordisk’s Wegovy® pill,

Key Points Novo Nordisk’s CagriSema could be a brand new growth driver for the company. Eli Lilly’s orforglipron is breaking into a new, lucrative market.

IJMS, Vol. 27, Pages 354: Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management International Journal of Molecular Sciences doi: 10.3390/ijms27010354 Authors:

Type 2 diabetes affects nearly 35 million Americans and more than 450 million people worldwide,1 and the numbers are still climbing. Behind these figures are

Effecty Weight loss can be complicated; finding the routine that works for you isn’t easy. You may have heard of GLP-1s, a class of medications

Butyrate, a short-chain fatty acid (SCFA) produced in your colon through the bacterial fermentation of dietary fiber, is a metabolite byproduct that nourishes your colonocytes

Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs that treat type 2 diabetes, high blood sugar, and obesity by regulating insulin production

Comments

21st CENTURY PROBLEMS: I started a GLP-1 to save my own life. How friends reacted surprised me. I got on Ozempic after my doctor predicted

Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists have recently been suggested as effective therapies to treat or reduce the risk of developing secondary lymphedema in patients

A daily Wegovy pill has been approved for use in the U.S. When can you get it?  San Antonio Express-News Weight-loss pill approval set to accelerate

Alright, hear me out before you downvote me into oblivion. I’ve been thinking a lot about the sudden, aggressive push behind these GLP-1 drugs like

submitted by /u/ddx-me [link] [comments]

$ISRG – Deciphering the Durability of a Surgical Revolution Intuitive Surgical, Inc. BATS:ISRG KalaGhazi Intuitive Surgical, Inc. (NASDAQ: ISRG) stands at a critical inflection point